Google News – EMA (biotech/pharma) External News
Biotechnology Articles
Google News – EMA (biotech/pharma) External News
MaaT Pharma: EMA Issues Negative Opinion on Xervyteg, Reassessment Requested - Idéal Investisseur
Google News – EMA (biotech/pharma) External News
Latest CHMP decisions led by recommendation to revoke approval of Tavneos - FirstWord Pharma
Google News – EMA (biotech/pharma) External News
MaaT Pharma Announces Plan to Request Re-Examination Following Negative CHMP Opinion for MaaT013 for the treatment of acute Graft-versus-Host Disease - businesswire.com
Google News – EMA (biotech/pharma) External News
MaaT Pharma challenges EMA rejection of Xervyteg with re-examination request for aGvHD - allsci.com
Google News – Biopharma External News
At BIO, tension over China biotech deal regulation looms - BioPharma Dive
Google News – EMA (biotech/pharma) External News
June 2026 batch of EMA/CHMP recommendations - thepharmaletter.com
Google News – EMA (biotech/pharma) External News
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks - MedCity News
Industry News External News
[Bio USA] Korea Exchange courts global biotech IPOs at Bio USA - The Korea Herald
Google News – FDA (biotech/pharma) External News
Otsuka posts phase 3b ADHD trial win ahead of looming FDA approval decision - Fierce Biotech
Google News – Oncology External News
BIO 2026: How a gut feeling transformed cancer treatment forever - Fierce Biotech
Google News – FDA (biotech/pharma) External News
Pharmalittle: We're reading about an FDA commissioner candidate, Germany's plans for drug prices, and more - STAT
Google News – Oncology External News
Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma - BioSpace
Google News – Oncology External News
Novartis pays Antares $105M to illuminate undruggable cancer targets - Fierce Biotech
Google News – Oncology External News